SALE EXTENDED
MarketBeat All Access
Start your 30-day free trial,
then continue your subscription for 50% off.
TODAY ONLY!
Claim Your Discount
×
S&P 500   3,641.87 (-2.74%)
DOW   29,322.64 (-2.02%)
QQQ   267.89 (-4.24%)
AAPL   140.03 (-3.71%)
MSFT   234.08 (-5.15%)
META   133.09 (-4.30%)
GOOGL   98.64 (-2.74%)
AMZN   114.25 (-5.03%)
TSLA   223.27 (-6.24%)
NVDA   120.60 (-8.15%)
NIO   13.74 (-6.97%)
BABA   81.05 (-3.88%)
AMD   58.59 (-13.65%)
T   14.94 (-2.48%)
MU   52.70 (-3.52%)
CGC   2.80 (-25.33%)
F   12.18 (-1.46%)
GE   64.34 (-2.84%)
DIS   96.84 (-3.20%)
AMC   6.48 (-8.99%)
PYPL   90.00 (-4.68%)
PFE   42.06 (-2.39%)
NFLX   225.37 (-6.10%)
S&P 500   3,641.87 (-2.74%)
DOW   29,322.64 (-2.02%)
QQQ   267.89 (-4.24%)
AAPL   140.03 (-3.71%)
MSFT   234.08 (-5.15%)
META   133.09 (-4.30%)
GOOGL   98.64 (-2.74%)
AMZN   114.25 (-5.03%)
TSLA   223.27 (-6.24%)
NVDA   120.60 (-8.15%)
NIO   13.74 (-6.97%)
BABA   81.05 (-3.88%)
AMD   58.59 (-13.65%)
T   14.94 (-2.48%)
MU   52.70 (-3.52%)
CGC   2.80 (-25.33%)
F   12.18 (-1.46%)
GE   64.34 (-2.84%)
DIS   96.84 (-3.20%)
AMC   6.48 (-8.99%)
PYPL   90.00 (-4.68%)
PFE   42.06 (-2.39%)
NFLX   225.37 (-6.10%)
S&P 500   3,641.87 (-2.74%)
DOW   29,322.64 (-2.02%)
QQQ   267.89 (-4.24%)
AAPL   140.03 (-3.71%)
MSFT   234.08 (-5.15%)
META   133.09 (-4.30%)
GOOGL   98.64 (-2.74%)
AMZN   114.25 (-5.03%)
TSLA   223.27 (-6.24%)
NVDA   120.60 (-8.15%)
NIO   13.74 (-6.97%)
BABA   81.05 (-3.88%)
AMD   58.59 (-13.65%)
T   14.94 (-2.48%)
MU   52.70 (-3.52%)
CGC   2.80 (-25.33%)
F   12.18 (-1.46%)
GE   64.34 (-2.84%)
DIS   96.84 (-3.20%)
AMC   6.48 (-8.99%)
PYPL   90.00 (-4.68%)
PFE   42.06 (-2.39%)
NFLX   225.37 (-6.10%)
S&P 500   3,641.87 (-2.74%)
DOW   29,322.64 (-2.02%)
QQQ   267.89 (-4.24%)
AAPL   140.03 (-3.71%)
MSFT   234.08 (-5.15%)
META   133.09 (-4.30%)
GOOGL   98.64 (-2.74%)
AMZN   114.25 (-5.03%)
TSLA   223.27 (-6.24%)
NVDA   120.60 (-8.15%)
NIO   13.74 (-6.97%)
BABA   81.05 (-3.88%)
AMD   58.59 (-13.65%)
T   14.94 (-2.48%)
MU   52.70 (-3.52%)
CGC   2.80 (-25.33%)
F   12.18 (-1.46%)
GE   64.34 (-2.84%)
DIS   96.84 (-3.20%)
AMC   6.48 (-8.99%)
PYPL   90.00 (-4.68%)
PFE   42.06 (-2.39%)
NFLX   225.37 (-6.10%)
NASDAQ:OTIC

Otonomy - OTIC Stock Forecast, Price & News

$0.28
-0.01 (-2.17%)
(As of 10/7/2022 01:33 PM ET)
Add
Compare
Today's Range
$0.28
$0.29
50-Day Range
$0.25
$1.43
52-Week Range
$0.24
$2.59
Volume
3,255 shs
Average Volume
389,320 shs
Market Capitalization
$15.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50

Otonomy MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
1,507.1% Upside
$4.50 Price Target
Short Interest
Healthy
1.32% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.73) to ($0.58) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.08 out of 5 stars

Medical Sector

546th out of 1,075 stocks

Pharmaceutical Preparations Industry

248th out of 537 stocks

OTIC stock logo

About Otonomy (NASDAQ:OTIC) Stock

Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Receive OTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Otonomy and its competitors with MarketBeat's FREE daily newsletter.

OTIC Stock News Headlines

Otonomy (NASDAQ:OTIC) Now Covered by Analysts at StockNews.com
Otonomy Q2 2022 Earnings Preview - Seeking Alpha
See More Headlines
Receive OTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Otonomy and its competitors with MarketBeat's FREE daily newsletter.

OTIC Company Calendar

Last Earnings
7/25/2022
Today
10/07/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OTIC
Employees
51
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.50
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+1,507.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-51,180,000.00
Pretax Margin
-150,065.70%

Debt

Sales & Book Value

Annual Sales
$130,000.00
Book Value
$0.97 per share

Miscellaneous

Free Float
51,804,000
Market Cap
$15.96 million
Optionable
Optionable
Beta
1.51

Key Executives

  • Dr. David Allen Weber (Age 62)
    Pres, CEO & Director
    Comp: $907.68k
  • Mr. Paul E. Cayer (Age 60)
    Chief Financial & Bus. Officer
    Comp: $598.22k
  • Dr. Allen F. Ryan Ph.D.
    Co-Founder and Member of the Advisory Panel
  • Dr. Rick Adam Friedman M.D.
    Ph.D., Co-Founder and Member of the Advisory Panel
  • Dr. Alan Charles Foster Ph.D. (Age 66)
    Chief Scientific Officer
  • Ms. Breianna Bowen
    VP of HR
  • Ms. Barbara M. Finn
    Sr. VP of Regulatory Affairs & Quality Assurance
  • Dr. Fabrice Piu Ph.D.
    Sr. VP of Preclinical Devel.
  • Mr. David Skarinsky
    Sr. VP of Clinical
  • Mr. James Branch CPA
    VP of Fin. & Controller













OTIC Stock - Frequently Asked Questions

Should I buy or sell Otonomy stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OTIC shares.
View OTIC analyst ratings
or view top-rated stocks.

What is Otonomy's stock price forecast for 2022?

3 brokerages have issued 1 year target prices for Otonomy's shares. Their OTIC share price forecasts range from $3.00 to $6.00. On average, they expect the company's stock price to reach $4.50 in the next year. This suggests a possible upside of 1,507.1% from the stock's current price.
View analysts price targets for OTIC
or view top-rated stocks among Wall Street analysts.

How have OTIC shares performed in 2022?

Otonomy's stock was trading at $2.08 at the start of the year. Since then, OTIC shares have decreased by 86.5% and is now trading at $0.28.
View the best growth stocks for 2022 here
.

When is Otonomy's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our OTIC earnings forecast
.

How were Otonomy's earnings last quarter?

Otonomy, Inc. (NASDAQ:OTIC) announced its earnings results on Monday, July, 25th. The biopharmaceutical company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.01. During the same period in the previous year, the firm earned ($0.19) earnings per share.

What other stocks do shareholders of Otonomy own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Otonomy investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird (), Wellington Shields () and Macquarie ().

What is Otonomy's stock symbol?

Otonomy trades on the NASDAQ under the ticker symbol "OTIC."

How do I buy shares of Otonomy?

Shares of OTIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Otonomy's stock price today?

One share of OTIC stock can currently be purchased for approximately $0.28.

How much money does Otonomy make?

Otonomy (NASDAQ:OTIC) has a market capitalization of $15.96 million and generates $130,000.00 in revenue each year. The biopharmaceutical company earns $-51,180,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis.

How can I contact Otonomy?

Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The official website for the company is www.otonomy.com. The biopharmaceutical company can be reached via phone at (619) 323-2200, via email at ir@otonomy.com, or via fax at 619-291-9190.

This page (NASDAQ:OTIC) was last updated on 10/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.